Recent News
Nov 25, 2025 — BridgeBio announced management will present at the Piper Sandler and EvercoreISI investor conferences on Dec 2–3. Nov 19, 2025 — the company reported inducement RSU grants covering 34,199 common shares to new employees. Oct 3 and Sept 10, 2025 — earlier inducement grants disclosed for additional new hires. Dec 2, 2025 — coverage notes highlight strong Attruby sales and reported Phase 3 progress for BBP‑418 and encaleret program updates, with commercial uptake and late‑stage readouts cited as growth drivers.
Technical Analysis
ADX sits at 46.62, indicating a very strong trend; such strength increases the likelihood that recent directional moves persist into the near term, which supports the current price momentum relative to WMDST’s valuation.
DI+ registered a peak‑and‑reversal at 31.06, a bearish directional signal that suggests prior buying pressure waned; DI– decreased to 9.90, a bullish directional move that signals diminishing selling pressure. Together these directional readings create mixed directional signals for the immediate price path.
MACD equals 3.20 with the MACD line rising above the 2.85 signal line; this cross and the increasing MACD trend constitute a bullish momentum signal that aligns with short‑term upside bias into any nearing consolidation.
MRO sits positive at 37.63 and rising, which indicates the current price sits above the modeled target and implies a likelihood of downward pressure toward fair value; this contrasts with momentum indicators and tempers the short‑term upside case.
RSI at 64.4 and increasing indicates rising buying momentum and approaches overbought territory; the indicator favors consolidation or a pause before continuation if sellers reappear.
Price relationships favor a bullish bias: close $71.78 trades above the 12‑day EMA $68.74, the 20‑day average $68.01, the 50‑day average $59.76 and the 200‑day average $45.36. The super trend lower at $65.93 and the 12‑day EMA provide nearby technical support consistent with WMDST’s under‑valued assessment.
Bollinger metrics show the stock sitting slightly above the 1× upper band ($71.13) and well inside the 2× band ($74.25), indicating elevated short‑term price levels but not extreme dispersion; recent volume (2.40M) slightly exceeds the 10‑day average (2.31M), supporting the move without showing exhaustive participation compared with the 200‑day average (2.83M).
Ichimoku lines place price above Tenkan‑Sen $67.27 and Kijun‑Sen $62.61 and well above the cloud (Senkou A $53.90 / Senkou B $49.79), reinforcing a bullish trend bias while higher short‑term beta (42‑day 1.66 vs 52‑week 1.11) warns of greater recent volatility.
Fundamental Analysis
Revenue totaled $120,700,000 with revenue growth listed at 9.17% (overall) but showing a revenue growth year‑over‑year decline of 64.76% and a QoQ change of –276.19%; those YoY and QoQ figures reflect timing and program revenue fluctuations inherent in a transitioning commercial biotech. Gross margin sits at 94.56%, reflecting product‑level profitability where sales exist.
Operating metrics show operating income of –$136,358,000 and EBIT of –$138,333,000, producing an EBIT margin of –114.61%, a slight deterioration versus the industry peer mean EBIT margin of –112.94% (industry peer mean). EBIT margin quarter‑over‑quarter fell by 12.02% and year‑over‑year declined by 97.78%.
EPS actual came in at –$0.72 versus an estimate of –$0.78, yielding an EPS surprise of +7.69%, which narrowed expected losses and demonstrates marginal operational progress in the quarter covered.
Cash and liquidity position shows $645,942,000 in cash and short‑term investments, a cash ratio of 2.98 and a current ratio of 3.88, indicating substantial near‑term liquidity to fund R&D and commercialization. Free cash flow remains negative at –$112,444,000, and free cash flow yield stands at –1.12% with a year‑over‑year decline of 70.09%.
Balance sheet leverage presents total debt of $1,859,737,000 with net debt of $1,208,065,000; debt‑to‑assets reads 186.30%, well above the industry peer mean of 21.33%, reflecting the company’s capital structure after recent financings and commercial investment. Return on equity registers at 9.45%, above the industry peer mean of –0.62%.
R&D expense reached $112,874,000, consistent with ongoing late‑stage programs including Attruby commercialization and multiple Phase 3 assets. WMDST values the stock as under‑valued given the combination of pipeline value, improving commercial revenue, and strong cash reserves despite negative profitability metrics.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-09-30 |
| REPORT DATE: | 2025-10-29 |
| NEXT REPORT DATE: | 2026-01-28 |
| CASH FLOW | Begin Period Cash Flow | $ 751.1 M |
| Operating Cash Flow | $ -109.57 M | |
| Capital Expenditures | $ -2.87 M | |
| Change In Working Capital | $ -3.93 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ -106.00 M | |
| End Period Cash Flow | $ 645.1 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | $ 120.7 M | |
| Forward Revenue | $ 24.3 M | |
| COSTS | ||
| Cost Of Revenue | $ 6.6 M | |
| Depreciation | $ 1.4 M | |
| Depreciation and Amortization | $ 1.4 M | |
| Research and Development | $ 112.9 M | |
| Total Operating Expenses | $ 257.1 M | |
| PROFITABILITY | ||
| Gross Profit | $ 114.1 M | |
| EBITDA | $ -136.94 M | |
| EBIT | $ -138.33 M | |
| Operating Income | $ -136.36 M | |
| Interest Income | $ 6.2 M | |
| Interest Expense | $ 48.1 M | |
| Net Interest Income | $ -41.91 M | |
| Income Before Tax | $ -186.48 M | |
| Tax Provision | $ -1.54 M | |
| Tax Rate | 0.829 % | |
| Net Income | $ -182.74 M | |
| Net Income From Continuing Operations | $ -184.94 M | |
| EARNINGS | ||
| EPS Estimate | $ -0.78 | |
| EPS Actual | $ -0.72 | |
| EPS Difference | $ 0.06 | |
| EPS Surprise | 7.692 % | |
| Forward EPS | $ -0.77 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 998.2 M | |
| Intangible Assets | $ 28.8 M | |
| Net Tangible Assets | $ -1.96 B | |
| Total Current Assets | $ 839.4 M | |
| Cash and Short-Term Investments | $ 645.9 M | |
| Cash | $ 643.0 M | |
| Net Receivables | $ 116.5 M | |
| Inventory | $ 24.5 M | |
| Long-Term Investments | $ 25.5 M | |
| LIABILITIES | ||
| Accounts Payable | $ 18.7 M | |
| Short-Term Debt | — | |
| Total Current Liabilities | $ 216.6 M | |
| Net Debt | $ 1.2 B | |
| Total Debt | $ 1.9 B | |
| Total Liabilities | $ 2.9 B | |
| EQUITY | ||
| Total Equity | $ -1.93 B | |
| Retained Earnings | $ -3.63 B | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ -10.03 | |
| Shares Outstanding | 192.633 M | |
| Revenue Per-Share | $ 0.63 | |
| VALUATION | Market Capitalization | $ 10.0 B |
| Enterprise Value | $ 11.2 B | |
| Enterprise Multiple | -81.962 | |
| Enterprise Multiple QoQ | 20.226 % | |
| Enterprise Multiple YoY | 149.21 % | |
| Enterprise Multiple IPRWA | high: 52.77 median: 26.559 mean: 5.018 low: -79.113 BBIO: -81.962 |
|
| EV/R | 92.986 | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | -0.516 | |
| Asset To Liability | 0.342 | |
| Debt To Capital | -25.36 | |
| Debt To Assets | 1.863 | |
| Debt To Assets QoQ | 8.288 % | |
| Debt To Assets YoY | 26821.965 % | |
| Debt To Assets IPRWA | BBIO: 1.863 high: 1.045 mean: 0.213 median: 0.074 low: 0.0 |
|
| Debt To Equity | -0.962 | |
| Debt To Equity QoQ | -7.444 % | |
| Debt To Equity YoY | 25623.529 % | |
| Debt To Equity IPRWA | high: 1.461 mean: 0.193 median: 0.09 low: -0.897 BBIO: -0.962 |
|
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | -5.178 | |
| Price To Book QoQ | 7.31 % | |
| Price To Book YoY | 31.183 % | |
| Price To Book IPRWA | high: 17.968 mean: 7.131 median: 5.933 BBIO: -5.178 low: -8.555 |
|
| Price To Earnings (P/E) | -72.169 | |
| Price To Earnings QoQ | 63.345 % | |
| Price To Earnings YoY | 209.035 % | |
| Price To Earnings IPRWA | high: 56.753 mean: -2.825 median: -10.328 BBIO: -72.169 low: -93.179 |
|
| PE/G Ratio | 2.981 | |
| Price To Sales (P/S) | 82.93 | |
| Price To Sales QoQ | 6.283 % | |
| Price To Sales YoY | -95.333 % | |
| Price To Sales IPRWA | high: 1129.647 BBIO: 82.93 mean: 73.34 median: 25.506 low: 0.466 |
|
| FORWARD MULTIPLES | ||
| Forward P/E | -63.14 | |
| Forward PE/G | 2.608 | |
| Forward P/S | 411.356 | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | -0.431 | |
| ASSET & SALES | ||
| Asset Turnover Ratio | 0.116 | |
| Asset Turnover Ratio QoQ | 3.034 % | |
| Asset Turnover Ratio YoY | 3005.348 % | |
| Asset Turnover Ratio IPRWA | high: 0.438 mean: 0.117 BBIO: 0.116 median: 0.107 low: 0.0 |
|
| Receivables Turnover | 1.248 | |
| Receivables Turnover Ratio QoQ | 8.459 % | |
| Receivables Turnover Ratio YoY | -74.002 % | |
| Receivables Turnover Ratio IPRWA | high: 6.279 mean: 1.455 median: 1.412 BBIO: 1.248 low: 0.006 |
|
| Inventory Turnover | 0.307 | |
| Inventory Turnover Ratio QoQ | -6.691 % | |
| Inventory Turnover Ratio YoY | 4072.109 % | |
| Inventory Turnover Ratio IPRWA | high: 2.722 mean: 0.603 median: 0.37 BBIO: 0.307 low: -0.015 |
|
| Days Sales Outstanding (DSO) | 73.101 | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | 47.721 | |
| Cash Conversion Cycle Days QoQ | -110.283 % | |
| Cash Conversion Cycle Days YoY | -99.525 % | |
| Cash Conversion Cycle Days IPRWA | high: 1241.621 median: 189.366 mean: 188.893 BBIO: 47.721 low: -1809.09 |
|
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | 0.194 | |
| CapEx To Revenue | -0.024 | |
| CapEx To Depreciation | -2.053 | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ -82.05 M | |
| Net Invested Capital | $ -82.05 M | |
| Invested Capital | $ -82.05 M | |
| Net Tangible Assets | $ -1.96 B | |
| Net Working Capital | $ 622.8 M | |
| LIQUIDITY | ||
| Cash Ratio | 2.982 | |
| Current Ratio | 3.875 | |
| Current Ratio QoQ | -25.299 % | |
| Current Ratio YoY | 21.351 % | |
| Current Ratio IPRWA | high: 25.502 mean: 4.386 BBIO: 3.875 median: 3.195 low: 0.02 |
|
| Quick Ratio | 3.762 | |
| Quick Ratio QoQ | -25.999 % | |
| Quick Ratio YoY | 106.712 % | |
| Quick Ratio IPRWA | high: 13.391 BBIO: 3.762 mean: 2.778 median: 2.481 low: 0.02 |
|
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | -13.581 | |
| Cost Of Debt | 2.569 % | |
| Interest Coverage Ratio | -2.873 | |
| Interest Coverage Ratio QoQ | -24.919 % | |
| Interest Coverage Ratio YoY | -53.075 % | |
| Interest Coverage Ratio IPRWA | high: 815.709 mean: 41.559 median: 4.855 BBIO: -2.873 low: -1520.021 |
|
| Operating Cash Flow Ratio | -1.083 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | 559.99 | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | -7.586 % | |
| Revenue Growth | 9.167 % | |
| Revenue Growth QoQ | -276.187 % | |
| Revenue Growth YoY | -64.763 % | |
| Revenue Growth IPRWA | high: 301.849 % BBIO: 9.167 % mean: 8.025 % median: 4.118 % low: -259.856 % |
|
| Earnings Growth | -24.211 % | |
| Earnings Growth QoQ | 499.282 % | |
| Earnings Growth YoY | -113.299 % | |
| Earnings Growth IPRWA | high: 162.5 % median: -6.452 % mean: -13.041 % BBIO: -24.211 % low: -198.545 % |
|
| MARGINS | ||
| Gross Margin | 94.563 % | |
| Gross Margin QoQ | -2.206 % | |
| Gross Margin YoY | 21.062 % | |
| Gross Margin IPRWA | high: 105.39 % BBIO: 94.563 % median: 83.077 % mean: 79.611 % low: -35.147 % |
|
| EBIT Margin | -114.609 % | |
| EBIT Margin QoQ | -12.015 % | |
| EBIT Margin YoY | -97.782 % | |
| EBIT Margin IPRWA | high: 3270.865 % median: 36.648 % mean: -112.944 % BBIO: -114.609 % low: -8139.786 % |
|
| Return On Sales (ROS) | -112.973 % | |
| Return On Sales QoQ | -6.417 % | |
| Return On Sales YoY | -97.814 % | |
| Return On Sales IPRWA | high: 573.037 % median: 26.151 % BBIO: -112.973 % mean: -176.649 % low: -8613.378 % |
|
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ -112.44 M | |
| Free Cash Flow Yield | -1.123 % | |
| Free Cash Flow Yield QoQ | 12.978 % | |
| Free Cash Flow Yield YoY | -70.093 % | |
| Free Cash Flow Yield IPRWA | high: 30.655 % median: 0.815 % mean: 0.325 % BBIO: -1.123 % low: -57.887 % |
|
| Free Cash Growth | 31.092 % | |
| Free Cash Growth QoQ | -154.271 % | |
| Free Cash Growth YoY | -108.826 % | |
| Free Cash Growth IPRWA | high: 201.164 % BBIO: 31.092 % mean: 25.613 % median: 21.696 % low: -200.947 % |
|
| Free Cash To Net Income | 0.615 | |
| Cash Flow Margin | -194.43 % | |
| Cash Flow To Earnings | 1.284 | |
| VALUE & RETURNS | ||
| Economic Value Added | $ 0.04 | |
| Return On Assets (ROA) | -17.585 % | |
| Return On Assets QoQ | -5.171 % | |
| Return On Assets YoY | -20.813 % | |
| Return On Assets IPRWA | high: 30.5 % median: 0.602 % mean: -2.094 % BBIO: -17.585 % low: -66.968 % |
|
| Return On Capital Employed (ROCE) | -17.698 % | |
| Return On Equity (ROE) | 0.095 | |
| Return On Equity QoQ | -7.077 % | |
| Return On Equity YoY | -28.243 % | |
| Return On Equity IPRWA | high: 0.948 BBIO: 0.095 median: -0.002 mean: -0.006 low: -1.385 |
|
| DuPont ROE | 9.822 % | |
| Return On Invested Capital (ROIC) | 167.191 % | |
| Return On Invested Capital QoQ | -190.665 % | |
| Return On Invested Capital YoY | 292.301 % | |
| Return On Invested Capital IPRWA | BBIO: 167.191 % high: 31.965 % median: 4.232 % mean: -0.086 % low: -73.241 % |
|